# A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants

> **NCT04472897** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 92 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** GSK2556286
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04472897
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-30
- **Primary completion:** 2024-11-06
- **Final completion:** 2024-11-06
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** A decision to stop the study was made by the site and GSK project team based on pre-defined stopping criteria in the protocol
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04472897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04472897, "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04472897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*